Physicians’ Education Resource (PER) has launched Retina Resource, a comprehensive source of education and information on the ...

D-150 is a potential backbone therapy that is designed to provide multi-year sustained delivery of anti-VEGF (aflibercept and ...

Kalaris is focused on developing TH103, a novel, differentiated anti-VEGF agent engineered to potentially provide longer-lasting and increased ...

Kalaris is focused on developing TH103, a novel, differentiated anti-VEGF agent engineered to potentially provide longer-lasting and increased anti-VEGF activity to treat neovascular and exudative dis ...

Physicians’ Education Resource (PER®) is excited to announce the launch of Retina Resource, a comprehensive source of cutting-edge education and information on the latest innovations in anti-VEGF ...

Ixo-vec is a potential best-in-class one-time gene therapy designed to deliver long-term efficacy, reduce the burden of frequent anti-VEGF and ...

Obstructive sleep apnea is associated with higher rates of age-related macular degeneration development and progression.

Ixo-vec is a potential best-in-class one-time gene therapy designed to deliver long-term efficacy, reduce the burden of frequent anti-VEGF and improve vision outcomes for patients with wet AMD ARTEMIS ...

The updated guidelines note that patients with stage IV NSCLC who have EGFR exon 19 deletions or exon 21 L858R substitutions can receive osimertinib plus platinum doublet chemotherapy or amivantamab ...

Macular degeneration, particularly age-related macular degeneration, is a leading cause of vision loss worldwide. This ...

Continuous administration of ranibizumab with a port delivery system provides an alternative to frequent intravitreal ...

Q4 2024 Earnings Call Transcript March 10, 2025 Operator: Welcome to BioNTech’s Fourth Quarter and Full-Year 2024 Earnings ...